Introduction: Primary surgery and adjuvant chemotherapy is the standard treatment protocol in ovarian cancer patients. Neoadjuvant chemotherapy is one of the mode of treatment in patients with poor condition or advanced disease, not applicable for primary surgery. The aim of this study was the evaluation of this new therapy option comparable with standard method. Patients and methods: 319 patients with FIGO stage III and IV of ovarian cancer have been analyzed. In this group 50 women were treated by using neoadjuvant chemotherapy. 18 patients were operated after 3 cycles of chemotherapy and the rest 32 patients after 6 cycles. Results of the treatment were evaluated, taking into consideration disease free survival and number of complications. Parameters affecting treatment results were also analyzed. Results: The median of disease free survival in the group treated with adjuvant chemotherapy and operated after 3 cycles of chemotherapy, were as follows: 19 and 20 months. In the group operated after 6 cycles, the median of disease free survival was 15 months (p=0.27). The following parameters influenced on treatment results: optimal cytoreduction and tumor grading. There was no difference in complications rate between these groups.